[Cost-Effectiveness Analysis of Maribavir in Patients with Post-Transplant Cytomegalovirus Infection or Disease that are Refractory or Resistant to Conventional Therapy]. FE [Internet]. 2023 Dec. 7 [cited 2025 Dec. 29];24(1). Available from: https://journals.seedstm.com/index.php/FE/article/view/1548